Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Ofatumumab and Bendamustine Followed By Ofatumumab Maintenance in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma after Prior Rituximab

Kathryn S. Kolibaba, MD, Mikhail Shtivelband, MD PhD, Edwin C. Kingsley, MD, Mehdi M. Moezi, MD, Donald Richards, MD PhD, Jeffrey P. Sharman, MD, Feng Xiaoshu, MS, Megan Cannan, B.S, Rafik Fellague-Chebra, MD, Roger M. Lyons, MD

Blood (2017) 130 (Supplement 1): 1500.

https://doi.org/10.1182/blood.V130.Suppl_1.1500.1500

Published: 2017

Journal Articles

Incidence, Clinical Profile and Outcome of Patients with Deep Vein Thrombosis and Pulmonary Embolism at a Community Hospital

Pragathi Balakrishna, MD, Mehdi M. Moezi, MD, Furquan Pathan, MD

Blood (2017) 130 (Supplement 1): 5585.

https://doi.org/10.1182/blood.V130.Suppl_1.5585.5585

Published: 2017

Journal Articles

A Retrospective Study to Evaluate the Incidence and Severity of Peripheral Neuropathy for Relapsed/Refractory Multiple Myeloma Patients upon Retreatment with Bortezomib

James R. Berenson, MD, Jacob D. Bitran, MD, Imad Tabbara, MD FACP, Jose Lutzky, MD, Laura V. Stampleman, MD, Sikander Ailawadhi, MD, Ronald Steis, MD, Mehdi M. Moezi, MD

Blood (2014) 124 (21): 3469.

https://doi.org/10.1182/blood.V124.21.3469.3469

Published: 2014

Journal Articles

A New Multinational Observational Study In Multiple Myeloma: Initial Report Of The PREAMBLE Study

Ravi Vij, MD, Mehdi M. Moezi, MD, Robin Foà, MD, Gordon Cook, MD, PhD, Antonio Palumbo, MD, Hakan Kaya, MD, Brian Durie, MD, David Cella, PhD, Lieven Annemans, PhD, Yun Su, MD, Pralay Mukhopadhyay, PhD, Trong K. Le, MPH, MS, Maria Teresa Petrucci, MD

Blood (2013) 122 (21): 1964.

https://doi.org/10.1182/blood.V122.21.1964.1964

Published: 2013

Journal Articles

A Multi-Center, Open-Label Study To Evaluate the Safety and Efficacy of Pentostatin, Cytoxan, and Rituxan (PCR) in the Treatment of Previously Untreated or Treated, Stage II, III or IV Chronic Lymphocytic Leukemia (CLL).

Raul R. Mena, MD, Mehdi M. Moezi, MD, Robert L. Robles, MD, Maureen Cooper, MD

Blood (2007) 110 (11): 1356.

https://doi.org/10.1182/blood.V110.11.1356.1356

Published: 2007

Journal Articles

Zoledronic Acid (ZOL) Markedly Improves Bone Mineral Density (BMD) for Patients (Pts) with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Bone Loss.

James R. Berenson, MD, Ori Yellin, MD, Ralph V. Boccia, MD, Marshall S. Flam, MD, Siu-Fun Wong, PharmD, Olcay Batuman, MD, Mehdi M. Moezi, MD, Donald Woytowitz, MD, Herb Duvivier, MD, Youram Nassir, MD, Regina A. Swift, RN

Blood (2007) 110 (11): 3606.

https://doi.org/10.1182/blood.V110.11.3606.3606

Published: 2007

Journal Articles

A Multi-Center, Open-Label Study To Evaluate the Safety and Efficacy of Pentostatin, Cytoxan, and Rituxan (PCR) in the Treatment of Previously Untreated or Treated, Stage II, III or IV CLL.

Raul R. Mena, MD, Robert Robles, MD, Michael Auerbach, MD, Mehdi M. Moezi, MD, David Headley, MD

Blood (2006) 108 (11): 4978.

https://doi.org/10.1182/blood.V108.11.4978.4978

Published: 2006

Journal Articles

First-Line Treatment of Multiple Myeloma with a Combination of Thalidomide, Dexamethasone, and Zoledronate (TDZ) in an Inner-City Population with High HIV Prevalence.

Uwe Klueppelberg, MD PhD, Eric Smith, PhD, Laurie Chen, MD, Chona M. Aloba, MD, Iuliana Shapira, MD, Mehdi M. Moezi, MD, Olcay Batuman, MD

Blood (2004) 104 (11): 4932.

https://doi.org/10.1182/blood.V104.11.4932.4932

Published: 2004

NARROW

Efficacy and Safety of Ofatumumab and Bendamustine Followed By Ofatumumab Maintenance in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma after Prior Rituximab

Incidence, Clinical Profile and Outcome of Patients with Deep Vein Thrombosis and Pulmonary Embolism at a Community Hospital

A Retrospective Study to Evaluate the Incidence and Severity of Peripheral Neuropathy for Relapsed/Refractory Multiple Myeloma Patients upon Retreatment with Bortezomib

A New Multinational Observational Study In Multiple Myeloma: Initial Report Of The PREAMBLE Study

A Multi-Center, Open-Label Study To Evaluate the Safety and Efficacy of Pentostatin, Cytoxan, and Rituxan (PCR) in the Treatment of Previously Untreated or Treated, Stage II, III or IV Chronic Lymphocytic Leukemia (CLL).

Zoledronic Acid (ZOL) Markedly Improves Bone Mineral Density (BMD) for Patients (Pts) with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Bone Loss.

A Multi-Center, Open-Label Study To Evaluate the Safety and Efficacy of Pentostatin, Cytoxan, and Rituxan (PCR) in the Treatment of Previously Untreated or Treated, Stage II, III or IV CLL.

First-Line Treatment of Multiple Myeloma with a Combination of Thalidomide, Dexamethasone, and Zoledronate (TDZ) in an Inner-City Population with High HIV Prevalence.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only